Mark Stein (@drmnstein) profile picture
Joined March 2013
Photo by Mark Stein (@drmnstein)Photo by Mark Stein (@drmnstein)Photo by Mark Stein (@drmnstein)Photo by Mark Stein (@drmnstein)Photo by Mark Stein (@drmnstein)Photo by Mark Stein (@drmnstein)Photo by Mark Stein (@drmnstein)Photo by Mark Stein (@drmnstein)Photo by Mark Stein (@drmnstein)Photo by Mark Stein (@drmnstein)
Lots of discussion @ASCO #GU21 about cytoreductive nephrectomy and the renal TME. Proud to share CYTOKIK trial in progress w cabozantinib/nivolumab before and after CN in pts w mcRCC
3
27
1
87
Love this concept presented by @DrKarieRuncie looking at sequencing in the highest risk subgroups of APMS prostate cancer CAPSTONE: ADT+docetaxel+abi-> ADT capi/abi vs ADT +capi+abi @Uromigos @OncoAlert #UroVoices #UroVoices
1
10
19
893
Thank you @Uromigos @brian_rini @tompowles1 and to all the amazing faculty and sponsors who contributed to makng #uromigoslive such a fun, thoughtful, and engaging meeting!
That's a wrap on #UromigosLive from Nashville! 🎸 The energy, the camaraderie, and a little friendly competition made this a weekend to remember 🏆 A huge thank you to everyone who made it all possible!
5
14
859
Thank you @Dr_Aggen! Valuable insights on trial design at #uromigoslive. Excited to see if we can build on Capitello-281 to improve outcomes for these high-risk patients. @Uromigos @neerajaiims @jackiebrown_MD @PGrivasMDPhD @NazliDizman @DrKarineTawagi @nataliagandur @OncoAlert
1
9
19
768
At #ESMO26 we introduced a new word, #RIPTAC, JNJ-6143. Introducing another innovation presented @sitcancer yesterday! FIH Investigational combo of Pasritamig our @JNJInnovMed KLK2xCD3 T-cell agent + our PSMA x CD28 co-stim JNJ-9401. Signal 1 & signal 2 together! #MyCompany
6
27
1
81
8,218
Mark Stein retweeted
Dr. @DrKarieRuncie of @ColumbiaCancer discusses Cyto-KIK, a phase II trial of cytoreductive surgery with nivolumab and cabozantinib in mRCC. The study reported a 59% objective response rate, including 11% complete responses. #DAVAGU
2
7
369
JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1 @ASCO @myESMO @AACR @kidneycan @DanaFarber_GU @OncoAlert
47
5
101
6,883
@DrScottTagawa leading an expert panel on navigating prostate cancer treatment. @Katie_Spina, James Kashanian, Doug Scherr
2
2
4
296
Mark Stein retweeted
Excited to share our new study in @JCOPO_ASCO examining the genomic landscape of early-onset GI cancers using >53,000 tumors from @AACR Project GENIE. @columbiacancer ascopubs.org/doi/10.1200/PO-…
3
10
1
37
3,326
Join us November 20 for the Genitourinary Oncology Symposium! A day bringing together experts across urology, medical oncology, radiation oncology, and more to examine what’s changing across prostate, bladder, and kidney cancer care. Sign up now: eventleaf.com/Attendee/Atten…
7
4
1,036
Great to see this article about the drug TIC10/ONC201 discovered in my academic lab in 2007 after we performed a chemical library screen while we were at @Penn. We’ve learned much about its mechanism of action over the years and it has been the thrill of a lifetime to see it get a first ever approval by the @US_FDA on August 6, 2025 for some of the most aggressive middle of the brain tumors with H3K27M mutation. The discovery followed an earlier discovery that the tumor suppressor p53 links to our innate immune system through control of TRAIL Death Receptor 5 in 1997, work done while my lab was supported by the Howard Hughes Medical Institute (@hhmi_science). The story is about basic science to clinical impact through precision oncology but there is still much more to be done to help patients. linkedin.com/posts/wafike_gr… @AACR @AmericanCancer @ASCO @AACI_Cancer @WIN_Consortium @Dr_R_Kurzrock @VivekSubbiah @SewantiLimaye @DrRoyHerbst @RoyJensenMD @DrJoannSweasy @DrPhilKantoff @DrRobWinn @billdahutmd @jrgralow @AACRPres @AshleySumrallMD @SeanLawler20 @NCIDirector @BrownUniversity @bcarneiro7 @lillian_siu
2
7
15
1,135
Mark Stein retweeted
Here's our latest, where we explored how to augment LLMs with constantly evolving precision oncology knowledge (h/t @moalmanac), followed by collaboration with medical oncologists to test their queries - congrats Helena Jun, et al!
4
19
1
56
4,888
Fantastic event dedicated to education and the impact of prostate cancer on our patients, hosted by @WeillCornell @WCMGUcancer @MSK_DeptOfMed @MSKCancerCenter @columbiacancer @nyphospital, at the NY Academy of Medicine. Sign up today! prostatesummit.org
Don’t miss the 7th annual #NYCProstateSummit dedicated to educating and empowering patients and loved ones impacted by #ProstateCancer hosted by @WeillCornell @nyphospital @MSKCancerCenter and @ColumbiaMed. All are welcome to attend, but RSVP is required: prostatesummit.org
7
12
2,279
‼️A #clinicaltrial led by Dr. Mark Stein is showing remarkable results against aggressive prostate cancers. Even at low doses, the immune-stimulating drug pasritamig shrank tumors in many late-stage patients. @ColumbiaMed Read more ➡️ @JNJNews cancer.columbia.edu/news/ope…
2
8
553
A new PET biomarker in men with high-risk metastatic castration-resistant prostate cancer. Total tumor volume prognostic for overall survival and predictive for benefit of Lu-177 PSMA-617. Great data from @ANZUPtrials ENZA-P led by @drlouiseemmett authors.elsevier.com/c/1lWie…~ Another 🇦🇺 @TheLancetOncol #theranostics
2
31
91
4,670
Mark Stein retweeted
Excited to share a new paper: tinyurl.com/49u5e6by @CellCellPress: a framework to accelerate variant classification, diagnosis & treatment of immune disorders & genetic disorders more broadly. Led by superstar, juggernaut & future dermatologist @zwalsh96
3
13
2
46
6,929
Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer aacrjournals.org/clincancerr… Research has shown that around 30% of advanced #ProstateCancer patients have Homologous Recombination / DNA Damage Repair (HRR) alterations (HRRalt), which have been linked to a poorer outlook in metastatic castrate-resistant prostate cancer. This study, the largest of its kind, investigated the impact of HRRalt on patients with metastatic hormone-sensitive prostate cancer (mHSPC). Analyzing data from 637 U.S. patients, researchers found that those with HRRalt (28.4% of the group) had a significantly shorter time to castrate-resistance (TTCR) when treated with either an androgen receptor pathway inhibitor or a taxane, compared to patients without HRRalt. While overall survival also trended less favorably in patients with HRRalt, these findings highlight the potential importance of HRRalt in mHSPC prognosis and could help guide future clinical trials and patient discussions. @chadihcmd @RyonGraf @ziremozay @ggebraelmd @nsayeghmd @maughanonc @EAntonarakis @neerajaiims @umangtalking @OncoAlert @Silke_Gillessen @AOmlin @bavilima @nataliagandur
17
29
3,141
Stage II seminoma: what’s best? JCO 2025. Review compares standard chemo/RT vs novel strategies: RPLND, de-escalated chemo, combo therapy. 👨‍⚕️ Men with IIA/IIB seminoma, LN ≤3 cm ✅ All: >90% cure 🔄 RPLND: relapse 10–30%, avoids chemo/RT in ~70% 1/2 @OncoAlert
2
43
1
103
11,844
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study ascopubs.org/doi/10.1200/JCO… This phase I trial of pasritamig, a novel bispecific T-cell–engaging antibody targeting KLK2 in metastatic castration-resistant #prostateCancer , demonstrated a manageable safety profile with mostly low-grade adverse events and minimal cytokine release syndrome. Showed promising preliminary antitumor activity, including a 42.4% PSA response rate and a median radiographic progression-free survival of 7.85 months, supporting further clinical development. @drmnstein @DebbieRobbrecht @DogerStart @MikeSchweizerMD @EmilianoCalvo_ @meavdongen @DrDariaGaut Ping @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur @bavilima
14
26
2,432